Viracta Therapeutics Inc
NASDAQ:VIRX
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.1550
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.1500/ 1
  • Ask / Lots
    0.1550/ 12
  • Open / Previous Close
    --- / 0.1550
  • Day Range
    ---
  • 52 Week Range
    0.1315
    1.3100
  • Volume
    2

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
VIRX
Viracta Therapeutics Inc
6.3M
-0.1x
---
ADIL
Adial Pharmaceuticals Inc
6.5M
-0.2x
---
GRI
GRI Bio Inc
6.2M
0.0x
---
CNSP
CNS Pharmaceuticals Inc
6.2M
0.0x
---
BCLI
Brainstorm Cell Therapeutics Inc
6.6M
-0.4x
---
RNAZ
Transcode Therapeutics Inc
6.6M
0.0x
---
As of 2024-11-26

Company Information

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Contact Information

Headquarters
2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007
Phone
858-400-8470
Fax
650-266-3501

Executives

Independent Chairman of the Board
Roger Pomerantz
President, Chief Executive Officer, Director
Mark Rothera
Chief Financial Officer
Michael Faerm
Senior Vice President - Finance
Melody Burcar
Chief Medical Officer
Darrel Cohen

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$6.3M
Revenue (TTM)
$0.00
Shares Outstanding
39.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.70
EPS
$-1.10
Book Value
$0.47
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.